Earnings Snapshot: GSK ups FY outlook as specialty medicines, vaccines, and general medicines boost Q3
Published 1 week ago
Oct 29, 2025 at 8:53 AM
Positive
Auto
[ ]
Seeking Alpha
MORE ON GSK
* GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon [https://seekingalpha.com/article/4829174-gsk-compelling-value-no-red-flags-ahead-of-earnings-blenrep-fda-decision-soon]
* GSK's Hidden Growth Engines Beyond HIV And Oncology [https://seekingalpha.com/article/4828903-gsk-hidden-growth-engines-beyond-hiv-oncology]
* GSK: Walmsley Out, Miels In - I'm Watching The CEO Transition From The Sidelines [https://seekingalpha.com/article/4826693-gsk-walmsley-out-miels-in-im-watching-the-ceo-transition-from-the-sidelines]
* GSK beats top-line and bottom-line estimates; raises FY25 outlook [https://seekingalpha.com/news/4509958-gsk-beats-top-line-and-bottom-line-estimates-raises-fy25-outlook]
* GSK secures exclusive rights to Syndivia’s preclinical ADC for advanced prostate cancer [https://seekingalpha.com/news/4508499-gsk-secures-exclusive-rights-to-syndivias-preclinical-adc-for-advanced-prostate-cancer]